AI Revolution In Prostate Cancer With Dr. Daniel Spratt The Dr. Geo Prostate podcast

AI has existed for decades, but modern deep learning is finally delivering precision decisions in clinic. Dr. Spratt details how ArteraAI’s predictive biomarker—validated on long-term randomized data—can spare roughly two-thirds of eligible men from ADT without compromising outcomes. We unpack ADT’s quality-of-life trade-offs, practical training and nutrition strategies to preserve muscle, and where AI is headed next (post-surgery models, higher-risk disease). You’ll also hear a clear framework for shared decision-making so men are treated as people, not just numbers.

Key Points

✅ AI meets prostate cancer. ArteraAI, developed by Dr. Daniel Spratt’s team, is now part of the NCCN guidelines—helping doctors know which patients truly benefit from hormone therapy.

✅ Two-thirds can skip ADT. Long-term data from the RTOG 9408 trial show most men can avoid the side effects of hormone therapy without affecting outcomes.

✅ Quality of life first. Treatments should improve survival or well-being—if they don’t, they shouldn’t be used.

✅ Lifestyle still matters. Exercise, protein, and resistance training help men on ADT preserve muscle and energy.

✅ The future is personalized. New AI models will soon guide therapy for higher-risk patients and integrate full-body health data for truly tailored care.

⏱️ Time-Stamped Highlights

00:00 – Why AI in prostate cancer now? From buzzword to bedside with ArteraAI.
01:30 – Deep learning vs. “human-defined” inputs; beyond Gleason to hundreds of slide features.
03:10 – Landmark validation: RTOG 9408 and how the model predicts who benefits from ADT.
05:00 – ADT trade-offs: longevity vs. libido, energy, bone/muscle; treat only if it improves life or survival.
07:15 – “Exercise is medicine”: the 10-minute rule, protein targets, and resistance training on ADT.
09:00 – Current indication: primarily intermediate-risk (Gleason 7) men receiving radiation.
10:45 – What’s next: models for higher-risk and post-prostatectomy patients; shorter-course ADT questions.
13:00 – “Black box” & explainability: why robust external validation matters for trust.
15:10 – Access & coverage: ordering via online portal; CMS coverage; what patients can ask their doctors.
17:20 – Shared decision-making: reduce PSA anxiety; treat the person, not the number.

___________________________________

🌱 Partner Offers

ProLon 5-Day Fasting Mimicking Diet — Enjoy fasting benefits with food. Supports cellular renewal, metabolic health, and fat loss. Special offer for our listeners: Get the ProLon kit for $148 → https://bit.ly/3TVehAx

AG1 by Athletic Greens — 75 high-quality vitamins, minerals, probiotics, and adaptogens in one daily scoop. Supports gut health, immunity, energy, and focus. Try it here → https://bit.ly/3mA2tVV

___________________________________

💪 Exclusive Membership

Want deeper insights? Join The Dr. Geo Prostate Podcast Exclusive Membership for curated transcripts, detailed show notes, expert resources, and member perks. → https://drgeo.com/membership

___________________________________

📌 Follow and Connect

📺 YouTube → Dr. Geo Prostate Podcast — https://www.youtube.com/@DrGeoProstatePodcast

🎧 All Episodes → Captivate.fm Archive — https://dr-geo-prostate-podcast.captivate.fm

📸 Instagram → https://bit.ly/DRGEO-INSTA-YT

📘 Facebook → https://bit.ly/POD-FB-DrGeo

💼 LinkedIn → https://bit.ly/DRGEO-LINKEDIN-YT

🛒 Supplements → XY Wellness https://bit.ly/3uJPC7Z | Mr. Happy https://bit.ly/3TE7tWE

🌐 DrGeo.com Website → https://bit.ly/43khht0

___________________________________

📣 Hashtags

#ProstateCancer #RadiationOncology #AIinHealthcare #ArteraAI #ADT #DigitalPathology #MensHealth #PrecisionOncology

___________________________________

⚠️ Disclaimer

This podcast is for educational purposes only and not medical advice. The views expressed are Dr. Geo’s and not those of his employer(s) or affiliated organizations. Use of this content is at your own risk. Geovanni Espinosa, N.D., assumes no liability for direct or indirect consequences, including economic loss, injury, illness, or death.

Key Points

✅ AI meets prostate cancer. ArteraAI, developed by Dr. Daniel Spratt’s team, is now part of the NCCN guidelines—helping doctors know which patients truly benefit from hormone therapy.

✅ Two-thirds can skip ADT. Long-term data from the RTOG 9408 trial show most men can avoid the side effects of hormone therapy without affecting outcomes.

✅ Quality of life first. Treatments should improve survival or well-being—if they don’t, they shouldn’t be used.

✅ Lifestyle still matters. Exercise, protein, and resistance training help men on ADT preserve muscle and energy.

✅ The future is personalized. New AI models will soon guide therapy for higher-risk patients and integrate full-body health data for truly tailored care.